cps.docx
- 文档编号:4212916
- 上传时间:2022-11-28
- 格式:DOCX
- 页数:26
- 大小:36.11KB
cps.docx
《cps.docx》由会员分享,可在线阅读,更多相关《cps.docx(26页珍藏版)》请在冰豆网上搜索。
cps
Pummelopeelisthedriedunripeoralmostripeexocarpofcitrusgrandis“tomentosa”orcitrusgrandisosbeck
Chemicalidentification
Shake0.5gofthepowderwith5mlofethanolfor5minutesandfilter.Evaporatethefiltratetodryness,adddropwiseantimonytrichloridesaturationsolutionin-chloroformandevaporateagaintodryness.Aviolet-redcolourisproduced.
前言目录
Index索引
Appendices附录
Monographs正文
Generalnotices
ThePharmacopoeiaofthePeople’sRepublicofChinaknownasChinesePharmacopoeiainabbreviationistheofficialgeneralscientificandtechnicalprovisionsfordrugqualitycontrolandadministration.
中华人民共和国药典,简称中国药典,是国家监督管理药品质量的法定技术标准。
WherethePharmacopoeiaisissuedforenforcementbythedrugregulatoryauthorityoftheStateCouncil,thesamedrugstandardofthepreviousPharmacopoeiaortheoriginalnationalstandardshallnotbeused.WhentheChinesePharmacopoeiaisquotedinthiscompendium,itdenotesthecurrenteditionofthePharmacopoeiaofthePeople’sRepublicofChina,exceptwhereaspecificeditionisindicated.
GeneralNoticesserveasthebasicguidelinesfortheproperinterpretationandapplicationoftheChinesePharmacopoeiainqualitycontrol.Itappliestoanyarticles,appendicesandgeneralstatementsrelatedtoqualitycontrolofdrugssoastoobviatereplicationinthiscompendium.TherelatedrequirementsinGeneralNoticesareofficialinthePharmacopoeia.
Thewording“unlessspecifiedotherwise”adoptedinGeneralNoticesandAppendicesindicatesthatappropriaterequirementisadmittedintherelatedmonographwherevertherequirementisnotconformtothatspecifiedinGeneralNoticesorAppendices.
ThedrugcitedinthePharmacopoeiashouldbethoseadmittedinthiseditionofPharmacopoeiasandcomplywiththerequirementsofcorrespondingmonographs.
TheGuidelinesstatedinAppendicesarenotconsideredasofficialrequirementsbutusedasstatementsinprinciplesappliedtotheimplementationofPharmacopoeia,monitoringofdrugquality,andrevisingorverifyingofdrugstandards.
TitlesandArrangements
1.TheChinesetitlesofdrugsadmittedinthemonographsarerecommendedaccordingtotheguidelineforthenomenclatureof“ChineseApprovedDrugNames”.TheChinesetitleofadrugisadoptedasofficialdesignation.Unlessspecifiedotherwise,the“InternationalNonproprietaryName”forpharmaceuticalsubstances(INN)isadoptedastheEnglishtitle.
Titlesoforganicchemicaldrugsareadoptedonthebasisof“GuidelinefortheNomenclatureofOrganicChemistry”publishedbytheChineseChemicalSociety.TheselectionofmainpartofitschemicalstructureisinlinewiththerulesoftheInternationalUnionofPureandAppliedChemistry(IUPAC).
2.Thechemicalstructureofthedrugsareportrayedaccordingto“GuidelinesforGraphicRepresentationofChemicalFormulae”recommendedbytheWorldHealthOrganization.
3.ThemonographsarearrangedalphabeticallyontheEnglishtitlesofdrugs.MonographsforformulatedpreparationsarefollowedthatofdrugsubstanceontitleinthePharmacopoeia.Monographsofexcipientsarelistedinseparatesection.Appendicesarearrangedintosectionsincludinggeneralrequirementsofformulatedpreparations,generaltestingmethodsandguidelines.
4.Themonographofeachdrugsubstanceordifferentdosageformsisstatedwithrespecttofollowingitems:
(1)Titleofdrugsubstanceordosageforms;
(2)Structuralformulaoforganicchemicals;
(3)Molecularformulaandmolecularweight;
(4)Sourcesorchemicalnameoforganicdrugs;
(5)Contentorpotency;(6)Formularyofthedosageform;(7)Processing;(8)Description;(9)Identification;(10)Test;(11)Assayofcontentorpotency;(12)Category;(13)Strengthorspecification;(14)Storage;(15)Preparation.
Specifications
5.Descriptionreferstotheappearance,odour,taste,solubilityandotherphysicalconstantsofthedrug.
(1)Appearanceofadrugistherequirementsofcolorandexternalappearance.
(2)Solubilityreferstothephysicalpropertyofadrugsubstance.Solventsdescribedunderthemonographandtherelevantsolubilitybehaviorsarestatedforreferenceforpurificationorpreparationofsolutionofadrugsubstance.Requirementshouldbestatedundertheitemoftestofthedrug,ifspecificqualitycontrolisneededforthesolubilitybehaviorofthesolventaccordingly.
Approximatesolubilitiesofdrugsareindicatedbythefollowingdescriptivephrases:
Verysolublereferstothat1g(ml)ofsoluteissolubleinlessthan1mlofsolvent;
Freelysolublereferstothat1g(ml)ofsoluteissolublein1mltolessthan10mlofsolvent;
Solublereferstothat1g(ml)ofsoluteissolublein10mltolessthan30mlofsolvent;
Sparinglysolublereferstothat1g(ml)ofsoluteissolublein30mltolessthan100mlofsolvent;
Slightlysolublereferstothat1g(ml)ofsoluteissolublein100mltolessthan1000mlofsolvent;
Veryslightlysolublereferstothat1g(ml)ofsoluteissolublein1000mltolessthan10000mlofsolvent;
Practicalinsolublereferstothat1g(ml)ofsoluteisnotsolublecompletelyin10000mlofsolvent.
Testingmethod:
unlessspecifiedotherwise,weighoutfinelypowderedsampleormeasureanamountofliquidsample,placethesampleinacertainvolumeofthesolventatatemperatureof25℃±2℃,shakestronglyfor30secondsatanintervalof5minutes.Observethesolubilitybehaviorfor30minutes.Itisconsideredtobecompletelysoluble,ifnoneoftheparticlesordropletofthesoluteisobserved.
(3)Physicalconstantsorparametersincludingrelativedensity,distillingrange,meltingpointormeltingrange,congealingpoint,specificrotation,refractiveindex,viscosity,specificabsorbance,iodinevalue,saponificationvalueandacidvalueetc.,areusefulfortestsforidentificationandgivesomeindicationofthedrugpurity.Itisoneofthechiefcriteriaforappraisalandassessmentofdrugquality.
6.Testingmethodsgivenintheidentificationsectionareintendedtogivesomeofthephysicalandchemicalcharacteristicsofthedrug;theyarenotdesignedtogiveafullconfirmationofthechemicalstructureofthedrug.
7.Testsectionunderthemonographincludesthetestingmethodsandacceptancecriteria,uniformityandpurityrequirementsformanufacturingprocess,whicharerelatedtothesafetyandefficacyofthedrug.Thespecifiedtestingitemsforimpuritiesareframedfromthosepossiblyexistedandproducedinthedrug,whichismanufacturedaccordingtotheapprovedmanufacturingprocessandstoredundernormalcondition,andthoseimpuritiesareneededtobecontrolled,suchasresidualsolventsandrelatedsubstances,etc.Receivingtotherelevantitemsmaybenecessaryforwherethemanufacturingprocessischanged.
Thedrugsubstanceintendedfordirectuseinthepreparationofsterilepowdersforinjectionshouldbetestedaccordingtothecorrespondingrequirementsoftheinjectionandconformwiththerequirements.Preparations,unlessspecifiedotherwise,mustcomplywiththerequirementsstatedunderthegeneralrequirementsforpreparationsofthePharmacopoeia.
8.ThetestingmethodsspecifiedundertheitemofAssayaredesignedtodeterminethecontentofactiveingredientofdrugsubstanceandpreparations,Chemical,instrumentalorbiologicalmethodscanusuallybeadopted.
9.Categoryreferstomainactionanduseofthedrugsoritsclassifiedscientificdesignation.Adrugisnotframedusinginothercategoryonthebasisofexperiencesinclinicalpractices.
10.strengthofpreparationsordosageformsreferstotheamount(unitsofpotency),labeledamount(%)orcontentofactiveingredientoringredientsineachampoule,tabletorotherunitcontainer,orpreparation.Forinjections,theexpression“1ml:
10mg”indicatesthattheinjectioncontains10mgofactiveingredientin1ml.specificationofweightorcontentmayalsobespecifiedforthemonographsofthepreparationinwhichtheformulaislistedortheconcentrationisindicated.
11.Storagereferstothebasicconditionsforstorageandpreservationofadrug.Itisstatedbythefollowingterms:
protectedfromlightreferstothatadrugshouldbekeptinlightresistantcontainersuchasambercoloredcontainer,oracolorlesstransparentorsemitransparentcontainerwrappedwithblackpaper.
Wellclosedreferstothatthecontainershouldbeabletoprotectthecontentfromextraneousmattersorloseofcontentsonnormalhandingcondition.
Tightlyclosedreferstothatthecontainershouldbeabletoprotectthecontentsfromefflorescence,deliquescence,volatilizationorinterferenceofextraneousmatters.
HermeticallysealedorTightlysealedreferstothatthecontainerissealedonfusionorsealedtightlywithsuitablematerialtoprotectagainstcontaminationandfrompermeabilityofairandmoisture.
Coolplacereferstothatthestoragetemperatureisnotexceeding20℃.
Coolanddarkplacereferstothatthecontaineriskeptinthedarkplace,protectedfromlightandtheambienttemperatureisnotexceeding20℃.
Coldplacereferstothatthecontaineriskeptatambienttemperatureof2-10℃.
Normaltemperaturereferstothatthecontaineriskeptatambienttemperatureof10-30℃.
12.thedrugsubstancesandexcipientsusedinpreparationsordosageformsshouldcomplywiththerequirementsstatedintheindividualmonographsofthiseditionofPharmacopoeia:
forthosenotadmittedinthiseditionofPharmacopoeiatheirspecificationsshouldbeestablished,whichshouldcomplywithrequirementsforPharmaceuticaluseandbeapprovedbythedrugregulatoryauthorityoftheStateCouncil.Wherethesamedrugsubstanceisusedfordifferencepreparations,especial
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- cps